Health Care Researchers Publish Study to Support FDA’s Approval of Additional Indication for Velcade Retreatment in Multiple Myeloma

August 15, 2014

A study conducted by Analysis Group Managing Principal Mei Sheng Duh, Vice President Patrick Lefebvre, and Senior Economist Marie-Hélène Lafeuille -- along with researchers from the California Pacific Medical Center, Tufts Medical Center, and Millennium: the Takeda Oncology Company -- was recently published in Clinical Lymphoma, Myeloma and Leukemia and cited in an Oncology Live article. The study, "Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients with Multiple Myeloma" (June 2014), was based on a systematic literature review of studies involving bortezomib-based retreatment in relapsed and/or refractory myeloma patients. The researchers found that relapsed patients tolerated reusing bortezomib to retreat myeloma, and that this approach might be highly effective.

This research was cited in a recent Oncology Live article, "FDA Expands Bortezomib Multiple Myeloma Label" (August 11, 2014). The U.S. Food and Drug Administration has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor.

Read the study abstract

Read an Oncology Live article